CDMOs as Strategic Partners: From Capacity Provider to Co-Creator of Value

For the pharmaceutical supply chain, the Covid-19 pandemic was less an external shock than an X-ray image. It made visible structural problems that had long existed but had not been prioritised, and in doing so it recalibrated the role of Contract Development and Manufacturing Organizations. Since then, the question is no longer only who supplies capacity, but who becomes part of the strategic value creation.

What the Pandemic Made Visible

Three findings stood out clearly. First, the vulnerability of global supply chains: shortages of active ingredients and packaging materials, such as glassware, showed how heavily the industry had become dependent on concentrated production sites, particularly in Asia. Second, increased expectations of the pharma companies, which demand more from CDMOs than capacity, namely strategic co-creation, transparency across the entire value chain and close involvement in production decisions. Third, national and regional production pressure, because regulatory initiatives in the EU and the USA aim to secure critical active ingredients and capacities regionally. CDMOs that merely wait out this development remain capacity providers. Those who help shape it become strategic partners.

The Four Building Blocks of the Transformation

The path from contract manufacturing to strategic partnership rests on four dimensions:

• Digitalisation of processes. AI-driven analyses, automation and digital twins create transparency in production and the supply chain. Real-time data shortens response times and enables proactive risk management instead of reactive firefighting.
• Investment in capabilities and capacities. Modern facilities, expanded active ingredient capacities, bioprocess development and support in research and development structurally differentiate a CDMO from a pure contract manufacturer.
• Sustainable relationships and joint planning. Strategic partnerships do not arise through contracts, but through shared goals: early involvement in product development, transparent communication and long-term commitments.
• Risk management and operational flexibility. Clearly defined escalation paths, flexible capacity models and scenario planning make it possible not only to absorb market changes but to use them as an opportunity.

Two Principles for the Coming Years

Two basic principles describe how successful collaborations will look in the future. The first is the transition from transactional to strategic: away from cooperation tied to individual orders, towards long-term partnerships with jointly defined growth paths, in which resilience, capacity assurance and investment decisions are made jointly rather than imposed unilaterally. The second is the integrated approach, which combines digital excellence, operational capability and strategic customer proximity into a single offering, so that one partner covers complex requirements across the entire development and production cycle. This turns CDMOs from service providers into co-creators of pharmaceutical value.

How Entourage Supports You

We support pharma companies and CDMOs across all phases of the collaboration: in the structured selection and assessment of partners based on requirement profiles, capacity analyses and strategic fit; in building supply chain resilience through dual sourcing and more robust procurement models for critical active ingredients and materials; in the regulatory safeguarding of technology transfers and site changes including CMC strategy, variation management and authority communication in line with GMP requirements; and in the selection and introduction of digital solutions along the value chain. In this way, a capacity relationship becomes a resilient strategic partnership.